Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATOSSA THERAPEUTICS, INC.

(ATOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
3.28(c) 3.28(c) 3.38(c) 3.51(c) 3.38 Last
6 767 630 2 568 479 4 131 071 4 349 072 3 982 440 Volume
-8.38% 0.00% +3.05% +3.85% -3.70% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -23,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -16,9x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -27,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -16,1x
Yield 2022 -
Capitalization 428 M 428 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 7
Free-Float 100,0%
More Financials
Company
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially... 
Sector
Biotechnology & Medical Research
Calendar
10/07 | 09:00amShareholder meeting
More about the company
All news about ATOSSA THERAPEUTICS, INC.
09/20ATOSSA THERAPEUTICS, INC.(NASDAQCM : ATOS) added to S&P Global BMI Index
CI
09/08ATOSSA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
09/07ATOSSA THERAPEUTICS : Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Add..
AQ
09/02ATOSSA THERAPEUTICS : to Move Forward With Phase 2 Trial of Oral Endoxifen for Mammographi..
MT
09/02ATOSSA THERAPEUTICS : Receives Approval from the Swedish Ethics Review Authority to Initia..
AQ
09/02Atossa Therapeutics Receives Approval from Swedish Ethics Review Authority to Initiate ..
CI
08/16ATOSSA THERAPEUTICS : Announces Second Quarter 2021 Financial Results - Provides Corporate..
AQ
08/13ATOSSA THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
08/13ATOSSA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
08/13Atossa Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
08/13ATOSSA THERAPEUTICS : Announces Second Quarter 2021 Financial Results - Provides Corporate..
AQ
08/05ATOSSA THERAPEUTICS : to Present at the BTIG Virtual Biotechnology Conference on August 9-..
AQ
07/30ATOSSA THERAPEUTICS : Seeks Shareholder Approval to Expand Authorized Common Shares -- Sha..
MT
07/26PHYSICIAN-SCIENTIST STEVEN QUAY : Forensic examination of Wuhan Institute of Virology COVI..
PR
07/19ATOSSA THERAPEUTICS : Shares Drop 11% With Trading Volume Slightly Above Daily Average
MT
More news
News in other languages on ATOSSA THERAPEUTICS, INC.
09/02Atossa va poursuivre l'essai de phase 2 sur l'endoxifène oral contre la densité mammogr..
2020BpiFrance confirme son intention de devenir un actionnaire de référence de Worldline
2019L'Europe dans le désordre avant la Fed, LVMH brille
More news
Chart ATOSSA THERAPEUTICS, INC.
Duration : Period :
Atossa Therapeutics, Inc. Technical Analysis Chart | ATOS | US04962H5063 | MarketScreener
Technical analysis trends ATOSSA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,38 $
Average target price 7,75 $
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Steven C. Quay Chairman, President & Chief Executive Officer
Kyle Guse CFO, Secretary & Chief Accounting Officer
Devon Payne Director-Clinical Operations
Bernadine Heather Fraser VP-Clinical, Regulatory & CMC Division
Stephen J. Galli Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATOSSA THERAPEUTICS, INC.255.79%444
MODERNA, INC.311.74%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.01%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-7.88%30 241